Atossa Therapeutics advances global patent strategy for Z-Endoxifen

Atossa Therapeutics (ATOS) announces key progress in its global intellectual-property strategy for Z-endoxifen, including the issuance of an Israeli patent and continued renewals that reinforce protection for the company’s lead program across major jurisdictions. The Israeli patent (No. 304863), titled, “Methods for Making and Using Endoxifen,” was granted on July 2, 2025, with priority to multiple U.S. provisional applications filed in 2017-2018. The allowed claims in Israel include oral, delayed-release dosage forms comprising at least 90% by weight Z-endoxifen, with optional impurity limits, defined release characteristics in gastric and intestinal media, dose strengths (e.g., 1-4 mg and 8 mg), and pharmacokinetic performance targets. The claims also cover manufacturing methods that enrich the Z-isomer via stepwise crystallization and solvent control. These protections align with Atossa’s quality-by-design approach to deliver a consistent, high-purity Z-endoxifen product. In parallel, Atossa received a Certificate of Patent Renewal from the Israel Patent Office confirming fee payment and renewal status for Patent No. 304863, further supporting the life-cycle management of Z-endoxifen IP in this jurisdiction.